MGX
Metagenomi, Inc. Common StockNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.32
P/S
2.01
EV/EBITDA
-0.56
DCF Value
$-104.95
FCF Yield
-176.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.3%
Operating Margin
-380.9%
Net Margin
-348.5%
ROE
-47.1%
ROA
-39.7%
ROIC
-47.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.9M | $-22.5M | $-0.60 |
| FY 2025 | $25.2M | $-87.9M | $-2.36 |
| Q3 2025 | $8.7M | $-20.4M | $-0.55 |
| Q2 2025 | $8.5M | $-19.9M | $-0.54 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.57
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.